Skip to main content
Premium Trial:

Request an Annual Quote

Human Protein Atlas, Bio-Rad, Ciphergen, ABI, Eagle, Alfa Wasserman, John Hopkins, ABRF, PerkinElmer, Sigma-Aldrich, Biosite, GenoLogics, Harvard, Lumera, Bruker

Premium
New Version of Human Protein Atlas Launched at HUPO
 
The second version of the Human Protein Atlas was launched during the Human Proteome Organization World Congress this week.
 
The atlas, available here contains 1,526 antibodies — more than double the 718 the atlas contained when it was launched last September during HUPO’s 2005 World Congress. It also contains 1.2 million images showing the expression and localization of human proteins. The new version will also link directly to SwissProt/UniProt and have a new cell atlas.
 
An advanced search function based on tissue searches will become available in the first quarter of 2007, said Mathias Uhlen, who is spearheading the HPA effort. At that time all expression data will be available for download.
 

 
Bio-Rad’s Purchase of Ciphergen Tools Business Delayed
 
Ciphergen’s sale of its proteomics tools business to Bio-Rad did not close on the anticipated Nov. 1 date.
 
After last week’s approval of the sale by Ciphergen’s shareholders, the company said it expected the transaction to close on or before Nov. 1. But on deadline, the proposed deal had not been completed.
 
A Bio-Rad spokeswoman declined to comment on the delay but said Wednesday that the deal could be finished within the next few days. As part of the deal, Bio-Rad is buying the SELDI technology from Ciphergen.
 
The two companies reached an agreement in August for the sale of Ciphergen’s proteomics tool business to Bio-Rad for $20 million in cash plus a $3 million equity investment by Bio-Rad into Ciphergen [See PM 08/17/06]. If completed, the deal would turn Ciphergen into a diagnostics company while Bio-Rad would significantly raise its profile in the proteomics space.
 

 
ABI, Eagle Collaborate on Molecular Detection Device
 
Applied Biosystems announced this week that it is collaborating with Eagle Research and Development to develop a single-molecule detection device invented by Eagle.
 
As part of the deal, ABI has an exclusive two-year option to license the technology. Further financial details of the collaboration were not disclosed.
 
In a statement, ABI said it believes the technology could have “significant implications for advancing personalized medicine based on its potential for faster, more efficient, and less expensive protein nucleic acid identification, protein-protein and protein/small molecule interaction measurements, and DNA sequencing.”
 
Eagle’s device, still in the prototype stage, is made up of an array of nanopores with each nanopore containing embedded semiconductors or field-effect transistors. Single molecules are driven through a nanopore by a voltage differential while the FET measures the three-dimensional charge profile of each molecule. This enables each molecule in a sample to be identified and quantified, ABI said.
 

 
Alfa Wasserman Inks Agreement With John Hopkins
 
Alfa Wasserman Proteomic Technologies announced an agreement this week with the John Hopkins University School of Medicine to develop methodologies and protocols for the isolation and enrichment of organelles and sub-cellular particles.
 
Jennifer Van Eyk will lead the effort for John Hopkins and will use AWPT’s AW Promatix 1000 instrument, which was launched this week [See accompanying story]. Van Eyk is director of the Johns Hopkins NHLBI Proteomics Group and the Johns Hopkins Bayview Proteomics Center.
 
Financial terms of the agreement were not disclosed.
 

 
ABRF Extends Deadline for Study Participation
 
The Proteomics Research Group of the Association of Biomolecular Resource Facilities has extended the deadline to Nov. 8 for participation in a study evaluating techniques for determining abundance differences in protein samples.
 
The study will focus on “the ability of core facilities to determine the identities
and phosphorylation sites of multiple proteins present in a single sample, with an objective of producing a phosphorylation standard for the community,” ABRF said in a statement.
 
Interested parties should request a study sample by sending an e-mail to [email protected]. The words “Sample Request” should be in the subject line. ABRF said it anticipates samples to be distributed on Nov. 15 and asks that resulting data be returned by Dec. 31.
 

 
PerkinElmer’s Q3 Revenues Up 7 Percent as Profits Slide 7 Percent
 
PerkinElmer last week said revenue for the third quarter increased 7 percent while profits fell 7 percent. Total receipts for the three months ended Sept. 30 increased to $387 million from $360 million year over year.
 
Income declined 7 percent to $29.7 million from $31.8 million in the third quarter of 2005.
 
Revenue from its life and analytical sciences division grew to $284 million from $259 million year over year.
 
PerkinElmer said it had around $207 million in cash and equivalents and around $7.5 million in marketable securities and investments as of Sept. 30. The company spent $24.8 million on research and development in the quarter, up $3 million from last year.
 

 
Sigma-Aldrich Says Q3 Revenues  Increase 7 Percent as Profits Rise 2 Percent
 
Revenues for the third quarter rose 7 percent to $441.4 million from $412 million a year ago, Sigma-Aldrich said last week.
 
For the three months ended Sept. 30, the company said net income rose to $205.2 million from $201 million a year ago, a 2 percent increase. The company said R&D spending rose 2 percent also. Sigma-Aldrich said it had $137 million in cash and cash equivalents.
 

 
Biosite Profits Dip 28 percent in Q3, Agrees to $100M in Stock Repurchase
 
Biosite’s revenues rose 7 percent to $74.6 million for the third quarter, compared to $69.7 million a year ago, the company said last week.
 
Net income for the quarter ended Sept. 30 fell 28 percent to $9 million from $12.6 million. R&D spending rose 19 percent to $12.5 million. Biosite reported it had $159 million in cash and marketable securities.
 
The company also announced it agreed to repurchase $100 million of its common stock after Biosite’s board approved to increase the repurchasing program from $50 million. Based on its Oct. 25 closing price of $47.55, the repurchase authorization represents 12 percent of the Biosite’s total market capitalization.
 

 
New Funding for GenoLogics
 
GenoLogics Life Sciences Software announced it has completed a second round of financing led by OVP Venture Partners in Seattle. The Victoria, British Columbia-based company did not disclose the amount of the funding.
 
Growth Works and Yaletown Venture Partners were the other investors in the second round. GenoLogics will use the money to further its market penetration strategy, the company said in a statement.
 
GenoLogic develops software to manage data from proteomic, genomic, and systems biology research.
 

 
Harvard Using Lumera Biosensor Platform for Diagnostic Development
 
Harvard Medical School is using Lumera’s ProteomicProcessor Biosensor to build next-generation discovery and diagnostic methods, the company said this week.
 
Harvard has been a beta site for the ProteomicProcessor since the middle of the year.
 
Harvard’s collaboration with Lumera is focused on integrating the ProteomicProcessor with Harvard’s Nucleic Acid Programmable Protein Array technology, which provides a method to generate a protein chip, to read and analyze the biochip.
 

 
Bruker Optics Acquisition Drives 22-Percent Q3 Revenue Increase
 
Bruker this week reported revenue of $104.9 million for the third quarter, a 22 percent increase from $85.9 million a year ago. Figures reflect the July 1 acquisition of Bruker Optics, which the company said accounted significantly for its revenue growth.
 
Profits rose to $3 million for three months ended Sept. 30, a 43 percent increase from $2.1 million a year ago.
 
The company did not break out the finances for its divisions separately, including Bruker Daltonics, which houses Bruker’s proteomics products.
 
The company said it had $44.1 million in cash and short-term investments at the end of the quarter. It did not disclose R&D costs.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.